CFDE Data Portal | Search LMNB1-DT

	Label	Description
	LMNB1-DT Gene (Entity type)	ENSG00000251072 - LMNB1 divergent transcript
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 4 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE199107 tryptophan 0 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS

LMNB1-DT

ENSG00000251072 - LMNB1 divergent transcript

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

A Gene Set from LINCS

GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

A Gene Set from LINCS

GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up

A Gene Set from LINCS

GSE146982 metformin 4 v 2 human up

A Gene Set from LINCS

GSE199107 tryptophan 0 v 7 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.